The objective of this study was to assess the evolution of viral load on Tenofovir (TDF)+Lamivudine (3TC) +Dolutegravir (DTG) (TLD) in PLVAs newly initiated on ART. The study took place at the Psycho Medico-Social Support Center (APMS) in N’Djamena over a period of 12 months. Sociodemographic data and viral load (VL) data were collected using a pre-established form. The VC examination was performed using the BIOCENTRIC molecular biology platform. A total of 120 patients were included in this study. Analyses showed a highly significant decrease in CVs during TLD follow-up (p < 0.0001). The proportion of patients with a suppressed viral load (CV <1000 copies/m) was 20,8% at M0, 98.3% at M3, 93.3% at M6 and 95% at M12. These results show that the Dolutegravir-based therapeutic line is remains an essential pillar in HIV ART.